ArticleMolecules (Basel, Switzerland)2022
The Antibacterial Activity of Egyptian Wasp Chitosan-Based Nanoparticles against Important Antibiotic-Resistant Pathogens.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Piperazine linked chitosan schiff base nanoparticles as a novel antibiofilm and antibacterial strategy against clinically relevant pathogens.Scientific reports · 2026Article
- Hepatoprotective Effects of Quercetin-Chitosan Nanoparticles on Nonalcoholic Fatty Liver Disease: In Vivo Study.Food science & nutrition · 2026Article
- Chitosan mitigates pan drug resistance in citrobacter freundii exhibiting AmpC and ESBL from Egyptian livestock.Scientific reports · 2025Article
- Effectiveness of Chitosan and Its Nanoparticles Against ampC- and ESBL-Producing Pan-Drug-ResistantPathogens (Basel, Switzerland) · 2025Article
- Predominance of enterotoxigenic Escherichia coli among ESBL/plasmid-mediated AmpC-producing strains isolated from diarrheic foals: a public health concern.Acta veterinaria Scandinavica · 2024Article
- Potential therapeutic biomolecules of hymenopteran venom against SARS-CoV-2 from Egyptian patients.Scientific reports · 2024Article
- Update on Chitin and Chitosan from Insects: Sources, Production, Characterization, and Biomedical Applications.Biomimetics (Basel, Switzerland) · 2024Review
- Nanoparticle Synthesis and Their Integration into Polymer-Based Fibers for Biomedical Applications.Biomedicines · 2023Review
- Enhanced Antibacterial Activity of Substituted Derivatives of NCR169C Peptide.International journal of molecular sciences · 2023Article
- Antimicrobial Compounds in Food Packaging.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current work discusses the production and characterization of new biodegradable nanoparticles for biomedical applications based on insect chitosan. Chitosan has numerous features due to the presence of primary amine groups in repeating units, such as antibacterial and anticancer activities. When polyanion tripolyphosphate is added to chitosan, it creates nanoparticles with higher antibacterial activity than the original chitosan. In this study, the ionic gelation technique was used to make wasp chitosan nanoparticles (WCSNPs) in which TEM and FTIR were used to investigate the physicochemical properties of the nanoparticles. In addition, the antibacterial activities of chitosan nanoparticles against extended-spectrum beta-lactamase (ESBL)- and carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.